GW-0742 POWDER – 1000MG / 1 GRAM
- E. Barrett-Connor, “Lower endogenous androgen levels and dyslipidemia in men with non-insulin- dependent diabetes mellitus,” Ann. Intern. Med., 1992.
- G. Tibblin, A. Adlerberth, G. Lindstedt, and P. Björntorp, “The pituitary-gonadal axis and health in elderly men: A study of men born in 1913,” Diabetes, 1996.
- S. M. Haffner, J. Shaten, M. P. Stern, G. D. Smith, and L. Kuller, “Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men,” Am. J. Epidemiol., 1996.
- R. K. Stellato, H. A. Feldman, O. Hamdy, E. S. Horton, and J. B. Mckinlay, “Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts Male Aging Study,” Diabetes Care, 2000.
- J. Y. Oh, E. Barrett-Connor, N. M. Wedick, and D. L. Wingard, “Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo Study,” Diabetes Care, 2002.
- D. E. Laaksonen et al., “Testosterone and Sex Hormone-Binding Globulin Predict the Metabolic Syndrome and Diabetes in Middle-Aged Men,” Diabetes Care, 2004.
- E. B. Geer and W. Shen, “Gender differences in insulin resistance, body composition, and energy balance,” Gend. Med., 2009.
- K. I. Birkeland, K. F. Hanssen, P. A. Torjesen, and S. Vaaler, “Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes,” J. Clin. Endocrinol. Metab., 1993.
- J. T. Dalton et al., “The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial,” J. Cachexia. Sarcopenia Muscle, vol. 2, no. 3, pp. 153–161, 2011.
- S. C. Kuo, P. M. Ku, L. J. Chen, H. S. Niu, and J. T. Cheng, “Activation of receptors δ (PPARδ) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro,” Horm. Metab. Res., 2013.
- F. M. Silva-Veiga, T. L. Rachid, L. de Oliveira, F. Graus-Nunes, C. A. Mandarim-de-Lacerda, and V. Souza-Mello, “GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice,” Mol. Cell. Endocrinol., 2018.
- M. Toral et al., “Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity,” J. Hypertens., 2015.
- Z. Haskova et al., “Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARβ/δ ligand GW0742,” Inflamm. Res., 2008.
- N. Wagner et al., “Peroxisome proliferator-activated receptor β stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin,” Cardiovasc. Res., 2009.
- S. A. Smith, G. R. Monteith, J. A. Robinson, N. G. Venkata, F. J. May, and S. J. Roberts-Thomson, “Effect of the peroxisome proliferator-activated receptor β activator GW0742 in rat cultured cerebellar granule neurons,” J. Neurosci. Res., 2004.
- A. Avogaro and S. V. De Kreutzenberg, “Mechanisms of endothelial dysfunction in obesity,” Clinica Chimica Acta. 2005.
- G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature. 2006.
- Y. X. Wang et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, 2003.
- W. R. Oliver et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proc. Natl. Acad. Sci. U. S. A., 2001.
- U. Risérus et al., “Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, Reduces oxidative stress, and increases fatty acid oxidation in moderately obese men,” Diabetes, 2008.
- C. H. Lee et al., “PPARδ regulates glucose metabolism and insulin sensitivity,” Proc. Natl. Acad. Sci. U. S. A., 2006.